{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:45:43Z","timestamp":1794012343605,"version":"4.8.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/P025838\/1, MR\/M008959\/1"],"award-info":[{"award-number":["MR\/P025838\/1, MR\/M008959\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The SARS-CoV-2 virus continues to cause significant morbidity and mortality worldwide from COVID-19. One of the major challenges of patient management is the broad range of symptoms observed. While the majority of individuals experience relatively mild disease, a significant minority of patients require hospitalisation, with COVID-19 still proving fatal for some. As such, there remains a desperate need to better understand what drives this severe disease, both in terms of the underlying biology, but also to potentially predict at diagnosis which patients are likely to require further interventions, thus enabling better outcomes for both patients and healthcare systems. Several lines of evidence have pointed to dysregulation of the complement cascade as a major factor in severe COVID-19 outcomes. How this is underpinned mechanistically is not known. Here, we have focussed on the role of the soluble complement regulators Complement Factor H (FH), its splice variant Factor H-like 1 (FHL-1) and five Factor H-Related proteins (FHR1-5). Using a targeted mass spectrometry approach, we quantified these proteins in a cohort of 188 plasma samples from controls and SARS-CoV-2 patients taken at diagnosis. This analysis revealed significant elevations in all FHR proteins, but not FH, in patients with more severe disease, particularly FHR2 and FHR5 (FHR2: 1.97-fold, p&amp;lt;0.0001; FHR5: 2.4-fold, p&amp;lt;0.0001). Furthermore, for a subset of 77 SARS-CoV-2 +ve patients we also analysed time course samples taken approximately 28 days post-diagnosis. Here, we see complement regulator levels drop in all individuals with asymptomatic or mild disease, but regulators remain high in those with more severe outcomes, with elevations in FHR2 over baseline levels in this group. These data support the hypothesis that elevation of circulating levels of the FHR family of proteins could predict disease severity in COVID-19 patients, and that the duration of elevation (or lack of immune activation resolution) may be partly responsible for driving poor outcomes in COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1032331","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T09:08:34Z","timestamp":1666170514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Levels of soluble complement regulators predict severity of COVID-19 symptoms"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna L.","family":"Tierney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajd Mohammed","family":"Alali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Rees-Unwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CITIID-NIHR BioResource COVID-19 Collaboration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Unwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"n2306","DOI":"10.1136\/bmj.n2306","article-title":"Covid-19: How is vaccination affecting hospital admissions and deaths","volume":"374","author":"Iacobucci","year":"2021","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100287","DOI":"10.1016\/j.xcrm.2021.100287","article-title":"Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions","volume":"2","author":"Filbin","year":"2021","journal-title":"Cell Rep Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2000279","DOI":"10.1002\/pmic.202000279","article-title":"Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches","volume":"21","author":"Ahsan","year":"2021","journal-title":"Proteomics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.652799","article-title":"Proteomics and machine learning approaches reveal a set of prognostic markers for COVID-19 severity with drug repurposing potential","volume":"12","author":"Suvarna","year":"2021","journal-title":"Front Physiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e202101099","DOI":"10.26508\/lsa.202101099","article-title":"A serum proteome signature to predict mortality in severe COVID-19 patients","volume":"4","author":"V\u00f6llmy","year":"2021","journal-title":"Life Sci alliance 4"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114167","article-title":"High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion","volume":"13","author":"Geyer","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00365","article-title":"Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 level","volume":"19","author":"D'Alessandro","year":"2020","journal-title":"J Proteome Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22418","DOI":"10.1038\/s41598-020-80120-8","article-title":"In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients","volume":"10","author":"Park","year":"2020","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cels.2021.05.005","article-title":"A time-resolved proteomic and prognostic map of COVID-19","volume":"12","author":"Demichev","year":"2021","journal-title":"Cell Syst"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","article-title":"Ultra-High-Throughput clinical proteomics reveals classifiers of COVID-19 infection","volume":"11","author":"Messner","year":"2020","journal-title":"Cell Syst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05171.x","article-title":"Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome","volume":"79","author":"Zilow","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1021-2","article-title":"Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection","volume":"26","author":"Ramlall","year":"2020","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2022","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","article-title":"The state of complement in COVID-19","volume":"22","author":"Afzali","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e20200199","DOI":"10.1590\/1678-4685-gmb-2020-0199","article-title":"MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19","volume":"44","author":"Bumiller-Bini","year":"2021","journal-title":"Genet Mol Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.815833","article-title":"Activation of complement components on circulating blood monocytes from COVID-19 patients","volume":"13","author":"Lage","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835156","article-title":"Complement activation via the lectin and alternative pathway in patients with severe COVID-19","volume":"13","author":"Niederreiter","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.smim.2019.101341","article-title":"Regulation of regulators: Role of the complement factor h-related proteins","volume":"45","author":"Cserhalmi","year":"2019","journal-title":"Semin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.755694","article-title":"Atypical hemolytic uremic syndrome-associated FHR1 isoform FHR1*B enhances complement activation and inflammation","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720183","article-title":"FHR-5 serum levels and CFHR5 genetic variations in patients with immune complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy","volume":"12","author":"Garam","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.05.015","article-title":"The impact of genetic-risk variants for age-related macular degeneration on circulating factor-h-like 1 and factor-h-related protein concentrations","volume":"108","author":"Cipriani","year":"2021","journal-title":"Am J Hum Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cels.2020.10.003","article-title":"Large-Scale multi-omic analysis of COVID-19 severity","volume":"12","author":"Overmyer","year":"2021","journal-title":"Cell Syst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.06.002","article-title":"Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration","volume":"108","author":"Lor\u00e9s-Motta","year":"2021","journal-title":"Am J Hum Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/bj2490593","article-title":"The complete amino acid sequence of human complement factor h","volume":"249","author":"Ripoche","year":"1988","journal-title":"Biochem J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.eclinm.2022.101495","article-title":"A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study","volume":"49","author":"Wang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.792135","article-title":"Differences in clinical characteristics between delta variant and wild-type SARS-CoV-2 infected patients","volume":"8","author":"Hu","year":"2021","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00720-5","article-title":"Estimating disease severity of omicron and delta SARS-CoV-2 infections","volume":"22","author":"Sigal","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1032331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T09:08:36Z","timestamp":1666170516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1032331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2022.1032331"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1032331","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"article-number":"1032331"}}